Octopharma has initiated a Phase II/III Study of its intravenous immunoglobulin preparation (IVIG) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
The study will be randomised, double-blind, placebo-controlled, adaptive and multi-centre, and will evaluate the safety and efficacy of Octapharma’s 10% novel intravenous immunoglobulin for CIDP treatment.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The results will be used to support the regulatory filing of IVIG in Europe and the US.
CIDP is a neurological disorder characterised by impaired sensation, areflexia, and slow onset of weakness.
